EpiVax announces the expansion of its laboratory and the implementation of streamlined, NAM-focused in vitro services
Summary
EpiVax expanded its Providence laboratory and more than doubled its lab space. The company says the upgrade strengthens its ability to run advanced immunology testing and support NAM-based immunogenicity risk assessment. It is positioning its in silico and in vitro platform as a one-stop partner for therapeutic developers who need human-relevant preclinical evaluation. The expanded capacity should help EpiVax take on more studies, support more partners, and deliver faster workflows for biologics, peptides, and emerging modalities.
Classifications
industries
Pharmaceuticals and Chemical
applications
Accounting and Taxes
AskAI Classifications
Labels
Bioinformatics Software
SaaS
Developer Tools
Linked Companies
EpiVax
$1M to $5M